Cardiac Vascular Sentral Kuala Lumpur Sdn. Bhd. announces updates to its purchase of Sooka Sentral

- Tan Sri Dato’ Dr. Yahya appointed as Chairman and Founding Partner of the Centre
- CVSKL to acquire Health Scan Malaysia Sdn. Bhd.
- Redeveloping Sooka Sentral into a premier cardiac and vascular hospital

Kuala Lumpur Sentral CBD, 28 October 2015 - Cardiac Vascular Sentral Kuala Lumpur Sdn. Bhd (CVSKL), a subsidiary of TE Asia Healthcare Partners (TE Asia), a TPG Capital portfolio company, wishes to announce today that it has appointed Tan Sri Dato’ Dr. Yahya as Chairman and Founding Partner of the cardiac and vascular centre (the Centre) in Kuala Lumpur Sentral CBD.

Tan Sri Dato’ Dr. Yahya was a founder and the former head and Medical Director of the National Heart Institute of Malaysia (Institut Jantung Negara), where he performed Malaysia’s first heart transplant in 1998. Upon the Centre’s opening, he will lead a team of established doctors, including interventional cardiologists (including electrophysiology) cardiothoracic surgeons, vascular surgeons, anesthetists, a nephrologist, and radiologists to provide services to the public.

Eng Aik Meng, TE Asia CEO, said “We are excited to be able to continue investing in the high growth healthcare sector in Malaysia, and are delighted to have a renowned Malaysian cardiac figure like Tan Sri Dato’ Dr. Yahya join us. CVSKL’s integrated cardiovascular centre represents TE Asia’s second in a series of investments as TE Asia looks to build a portfolio of high growth medical specialties across Asia.”

Meanwhile, speaking on his appointment, Tan Sri Dato’ Dr. Yahya, CVSKL Chairman, said “I am honoured to be a part of developing CVSKL. Malaysia has one of the highest mortality rates for cardiovascular diseases in the world, and there is a great need for cardiac and vascular facilities. Over the next year, I will look to assemble and establish a strong team of cardiac, vascular and related specialists, and ensure the hospital is well-equipped to deliver excellent care to our patients.”

According to the World Health Organisation, cardiovascular diseases account for 36% of all deaths in the region, compared to a global average of 31%. Despite this, Malaysia has one of the lowest numbers of cardiologists in the world, with approximately six cardiologists per one million citizens. This is significantly lower than the approximate ratio of 56 cardiologists per million in the United States.

In addition, CVSKL also wishes to announce that it has entered into a conditional sale and purchase agreement to acquire Health Scan Malaysia Sdn. Bhd. (Health Scan Malaysia), a premier medical centre offering some of the most comprehensive and advanced health screenings in Malaysia. As one of
Malaysia’s leading medical screening facilities that focuses on cardiovascular treatment, Health Scan Malaysia will support in developing the country’s foremost cardiac and vascular hospital.

“The addition of Health Scan Malaysia will enable us to jump start the healthcare screening offering we will have at CVSKL, and we look forward to working with the shareholders of Health Scan Malaysia to further advance the country’s healthcare sector,” said Eng Aik Meng.

Redeveloping Sooka Sentral into a premier cardiac and vascular hospital

Since 5 August 2015, CVSKL entered into a conditional sale and purchase agreement with Malaysian Resources Corporation Berhad (MRCB) to acquire the land and building in Kuala Lumpur Sentral CBD known as Sooka Sentral, which would be converted into a cardiac and vascular hospital. Plans for the hospital continue to make progress and are pending final regulatory approval before renovation work commences. Upon completion, the CVSKL-owned Centre will be the first privately-owned integrated preventive, diagnostic, surgical, therapeutic and rehabilitative cardiac and vascular centre in Malaysia.

Sooka Sentral is located at Kuala Lumpur Sentral CBD, an exclusive urban centre built around Malaysia’s largest transit hub, offering global connectivity, excellent investment opportunities, business convenience and an international lifestyle. It is a city-within-a-city, comprising Malaysia’s largest public transportation hub, the Stesen Sentral Kuala Lumpur (SSKL), green corporate office towers and business suites, 5-star international hotels, luxury condominiums, serviced apartments and a shopping mall.

The SSKL’s express rail service from the Kuala Lumpur International Airport will provide patients flying into Kuala Lumpur convenient access to CVSKL’s cardiac vascular hospital, which aims to attract patients from all over Malaysia and across Southeast Asia.

The building, when fully converted and reconfigured, will include a vein centre, a diagnostic business offering cardiovascular screenings including endoscopy procedures, catheterization labs, operating theatres, a hybrid lab/theatre, approximately 70 beds, and an Intensive Care, Coronary Care and Day Ward. CVSKL expects the Centre to be ready to open by the end of 2016.

About TPG Capital

TPG Capital is the global buyout group of TPG, a leading private investment firm founded in TPG is a leading global private investment firm founded in 1992 with over $74 billion of assets under management and offices in San Francisco, Fort Worth, Austin, Dallas, Houston, New York, Beijing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, Sao Paulo, Shanghai, Singapore and Tokyo. TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures and restructurings. The firm has
a strong history of healthcare investing and its well-known investments include Aptalis, Chindex International, EnvisionRX, Healthscope Immucor, Manipal Health Enterprises, Parkway Holdings, Par Pharmaceutical, Quintiles Transnational and Surgical Care Affiliates, among others. For more information, visit www.tpg.com.

About TE Asia Healthcare Partners
Established in 2014, TE Asia is the working title for a healthcare platform sponsored by TPG Capital. The goal of TE Asia is to identify and build a portfolio of healthcare delivery assets in Asia, in partnership with high quality medical specialists, with a focus on specialty clinics and hospitals. TE Asia is led by Mr. Eng Aik Meng, CEO, who has deep experience in acquiring and operating healthcare assets in Asia. Mr. Eng is currently a board member of Chindex International, China’s premier hospital group, and Healthscope, Australia’s leading healthcare operator with 45 private hospitals. TE Asia’s first investment opened in July 2015, the Hong Kong Integrated Oncology Centre (HKIOC) & Hong Kong Integrated Imaging & Endoscopy Diagnostic Centre (HKIEDC), a two-storey patient-centric oncology centre located in Central, Hong Kong, with the most advanced imaging technologies that help diagnose and guide therapy for different types of cancer. The integrated cardiovascular centre CVSKL represents the second in a series of investments planned by TE Asia to build a portfolio of high growth medical specialties across Asia.

About CVSKL
CVSKL is a planned integrated cardiovascular centre located in KL Sentral that will include a vein centre, a diagnostic business offering cardiovascular screenings including endoscopy procedures, catheterization labs, operating theatres, a hybrid lab/theatre, approximately 70 beds, and an Intensive Care, Coronary Care and Day Ward. CVSKL expects the Centre to be ready to open by the end of 2016.

END

For Media Enquiries, please contact:

TPG
Luke Barrett
LBarrett@tpg.com +1 (212) 601-4752

Brunswick Group
Siobhan Zheng +852 9131 5202
Melissa Ward +852 9016 1827
Liz Liang +852 9015 6858
TPGCOREASIA@brunswickgroup.com